Trial Profile
A multinational, prospective, non-interventional 24-week study to assess effectiveness and safety of initial combination therapy with vildagliptin/metformin in drug-naïve type 2 diabetes mellitus patients in a real life setting - INITIAL
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Vildagliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms INITIAL
- Sponsors Novartis Healthcare
- 15 Sep 2017 Primary endpoint (To assess the effectiveness of vildagliptin/metformin dual therapy (change in HbA1c from baseline to week 24) as initial combination in drug-naive adult type 2 diabetes patients) has been met, according to results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 15 Sep 2017 Results assessing effectiveness and safety of initial combination therapy with vildagliptin/metformin in drug-naive Type II diabetes patients, were presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.